Executive growth Biomapas appointed a new Chief Executive Officer in February 2025, signaling a potential strategic pivot or expansion plan. This presents an opening to discuss leadership-driven initiatives, potential new focus areas, and refreshed priorities in global regulatory, pharmacovigilance, and full lifecycle outsourcing.

Global expansion The company markets one-stop clinical research capabilities across Europe, CIS, MENA, and LATAM, indicating readiness to scale cross-region programs. This creates opportunities to propose multi-region studies, harmonized regulatory strategies, and centralized vendor management with Biomapas as a single partner.

Industry breadth Biomapas serves biopharma, medical devices, cosmetics, and food supplements, suggesting diverse outsourcing needs and potential for cross-vertical up-selling. Engage to map adjacent product areas, regulatory requirements, and pharmacovigilance support for broader contract scopes.

Data-driven Utilization of Power BI and other tech tools indicates a data-oriented project management approach. Propose advanced analytics, dashboards, and reporting services to optimize trial performance, KPI tracking, and regulatory submission readiness.

Scale and leadership Revenue in the mid hundreds of millions with a 201-500 employee base positions Biomapas as a mid-tier CRO with room to grow. Target opportunities around larger, multi-country programs, expanded capacity, and enhanced governance to win bigger, long-term collaborations.